Manuscripts
Showing 1554 manuscripts.
Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial
Citation
Lynne Mofenson, James V. Lavery, Grace John-Stewart, Patricia Flynn, Gerhard Theron, Shrikhant I. Bangdiwala, Dhayendre Moodley, Lameck Chinula, Lee Fairlie, Tumalano Sekoto, Tebogo J. Kakhu, Avy Violari, Sufia Dadabhai, Katie McCarthy, Seema K. Shah, Mary Glenn Fowler, Alex John London. Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. Clinical Trials. 2021. 18: 681-689. PMID: 34524048Year
2021
Journal
Clinical Trials
Study
1077HS, 1077FF, 1077BF
SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway.
Citation
Hanna J, Spector SA, Campbell GR, To RK. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway.. iScience. 2021. 24: 102295. PMID: 33718825Year
2021
Journal
iScience
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092
Citation
Lauren Ziemba, Anne Coletti, Renee Browning, Francesca Aweeka, John Moye, Philippa Musoke, Bobbie Graham, Christina Reding, Diane Costello, Jennifer Norman, Lubbe Wiesner, Emma Hughes, Meghan E. Whalen, Lynette Purdue, Blandina Theophil Mmbaga, Portia Kamthunzi, Rachel Kawalazira, Maxensia Owor, Kusum Nathoo, Camlin Tierney, Sarah Bradford. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Pediatric Infectious Disease Journal. 2021. PMID: 33464021Year
2021
Journal
Pediatric Infectious Disease Journal
Study
P1092
Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children
Citation
Elizabeth J. MacFarland, Coleen K. Cunningham, Petronella Muresan, Charlotte Perlowski, Jennifer Libous, Stephen A. Spector, Ram Yogev, Mariam Aziz, Suzanne Woods, Kimberli Wanionek, Peter L. Collins, Ursula J. Buchholz, Ruth A. Karron, Jessica E. Atwell. Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children. American Journal of Respiratory and Critical Care Medicine. 2021. 203: 594-603. PMID: 32871092Year
2021
Journal
American Journal of Respiratory and Critical Care Medicine
Study
IMPAACT 2011, IMPAACT 2012, IMPAACT 2013, P1114, IMPAACT 2000
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants
Citation
Petronella Muresan, Adrian McDermott, Edmund Capperelli, John Mascola, Charlotte Perlowski, Barney Graham, Patricia Morgan, IMPAACT P1112 Team, Betsy Smith, Rohan Hazra, Lynette Purdue, Paul Harding, Gerhard Theron, Hilda Mujuru, Allison Agwu, Murli Purswani, Mobeen Rathore, Britta Flach, Elizabeth McFarland, Alison Taylor, Coleen Cunningham, Bob Lin. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. Journal of Infectious Diseases. 2021. 224: 1916-1924. PMID: 34009371Year
2021
Journal
Journal of Infectious Diseases
Study
P1112
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Citation
Andrew A Wiznia, Jennifer J Kiser, Carmelita G Alvero, Kathleen H George, Diane G Costello, Christina A Reding, Cristina Barroso Hofer, Herta M Crauwels, Christine E MacBrayne, Richard M Rutstein, Bobbie Graham, IMPAACT P1090 Protocol Team, Lee Fairlie, Kathryn Lypen, Ellen Townley, Jack Moye Jr., Xavier Woot de Trixhe, Lotke Tambuyzer, Simon Vanveggel, Magda Opsomer. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 2021. 35: 1413-1421. PMID: 33831904Year
2021
Journal
AIDS
Study
P1090
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate
Citation
Brookie M Best , Jeremiah D Momper, Alice M Stek, Tim R Cressey, Mark Mirochnick, Edmund V Capparelli , Ahizechukwu C Eke, Kensuke Shoji. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy. 2021. 65: e02168-20. PMID: 33318014Year
2021
Journal
Antimicrobial Agents and Chemotherapy
Study
P1026S
Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development
Citation
Manuela Grimstein, Hari Cheryl Sachs, Mark Mirochnick, Kimberly Struble, Yodit Belew, Jian Wang, Edmund V. Capparelli, Brookie M. Best, Tamara Johnson, Jeremiah D. Momper, Anil R. Maharaj, Sherry Zhao, Mary Gockenbach. Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development. Frontiers in Pediatrics. 2021. 9: 721059. PMID: 34722417Year
2021
Journal
Frontiers in Pediatrics
Study
P1026S
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV
Citation
David E Shapiro, Gwendolyn B Scott, Mary E Paul, Irma L Febo, Derek Z Yang, Edmund V Capparelli, Jeremiah D Momper, Brookie M Best, Alice Stek, Sandra Burchett, Elizabeth Smith, Nahida Chakhtoura, Kayla Denson, Kittipong Rungruengthanakit, Kathleen George, Mark Mirochnick, Jiajia Wang, IMPAACT P1026s Protocol Team. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV. AIDS. 2021. 35: 1191-1199. PMID: 34076612Year
2021
Journal
AIDS
Study
P1026S
Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir
Citation
Natella Y Rakhmanin, Dionna J Green, Gilbert J Burckart, Tim R Cressey, Mark Mirochnick, Brookie M Best, John N van den Anker, André Dallmann, Xiaomei I Liu, Jeremiah D Momper. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clinical Pharmacokinetics. 2021. 60: 795-809. PMID: 33527213Year
2021
Journal
Clinical Pharmacokinetics
Study
P1026S